
<!-- We don't need full layout here, because this page will be parsed with Ajax-->
<!-- Top Navbar-->

<!-- Dynamic navbar for iOS theme -->
<div class="navbar">
    <div class="navbar-inner">
        <div class="left sliding">
            <a href="#" class="back">
                <i class="icon icon-back"></i><span>Back</span>
            </a>
        </div>
        <div class="center sliding">Paroxysmal Autonomic Instability</div>
    </div>
</div>


<div class="pages">
  <!-- Page, data-page contains page name-->
  <div data-page="paroxysmal-autonomic-instability" class="page">

    <!-- Scrollable page content-->
    <div class="page-content">

      <div class="content-block">
        <div class="content-block-title">Summary</div>
        <div class="content-block-inner">

          <p><strong>Signs:</strong> Hypertension, tachycardia, tachypnea, hyperthermia, spasticity, sweating due to surge in circulating catecholamines released from direct trauma to the regulatory centers.</p>

          <p><strong>Timing:</strong> Usually occurs in the first 2 weeks of injury, medical emergency.</p>

          <p>Paroxysmal sympathetic hyperactivity (PSH) is another term for PAI.</p>
        </div>
      </div>

      <div class="content-block">
        <div class="content-block-title">Diagnosis</div>
        <div class="content-block-inner">
          
         <p>There are no universally accepted criteria to date but some features can include:</p>
          <ul>
            <li>Temp &gt;38.3C</li>
            <li>HR >120 (or &gt;100 if on beta blockers)</li>
            <li>SBP >160 mmHg (or &gt;140 mmHg if on beta blockers or other antihypertensives)</li>
            <li>Respiratory Rate &gt;25 rpm</li>
            <li>Diaphoresis</li>
            <li>Posturing/severe dystonia, rigidity or spasticity</li>
          </ul>
       </div>
      </div>

      <div class="content-block">
        <div class="content-block-title">Management</div>
        <div class="content-block-inner">
          
         <p>Supportive measures include airway protection, sedation, pain control.</p>
         <p>Discuss case with TBI attending, but these recommendations act as initial management guidelines</p>
         <p>There are no standardized, specific criteria to date, but options include:</p>
         <div class="data-table">
            <table>
              <thead>
                <tr>
                  <th>Class</th>
                  <th>Drugs and Uses</th>
                </tr>
              </thead>

              <tbody>
                <tr>
                  <td>Lipophilic non-selective &beta;-blocker for hypertension, tachycardia, fever</td>
                  <td><span class="inlineHeader">Propranolol</span> 10mg PO, can repeat after 30 min if still tachycardic. max 80 mg/day divided in 3-4 doses</td>
                </tr>
                <tr>
                  <td>Opioids for tachycardia, vasodilation, allodynic response </td>
                  <td><span class="inlineHeader">morphine</span> 1-8mg, frequency according to the onset of PSH</td>
                </tr>
                <tr>
                  <td rowspan=3>GABA agonists</td>
                  <td><span class="inlineHeader">baclofen</span> (5mg TID for pain, clonus, rigidity)</td>
                </tr>
                <tr>
                  <td><span class="inlineHeader">gabapentin</span> (300mg TID for spasticity, allodynic response)</td>
                </tr>
                <tr>
                  <td><span class="inlineHeader">benzodiazepines</span> (for agitation, HTN, tachycardia, posturing)</td>
                </tr>

                <tr>
                  <td>Centrally acting &alpha;<sub>2</sub> agonists</td>
                  <td><span class="inlineHeader">clonidine</span> 0.1-0.3mg q12h (for HTN)</td>
                </tr>
                <tr>
                  <td>Dopamine agonists*</td>
                  <td><span class="inlineHeader">bromocriptine</span> 1.25-2.5mg q30 min prn with max dose 100 mg/day (for dystonia, fever, posturing)</td>
                </tr>
                <tr>
                  <td>NSAIDs</td>
                  <td><span class="inlineHeader">indomethacin</span> (25-50mg (but avoid with hemorrhagic injury or other bleeding risk)</td>
                </tr>
                <tr>
                  <td>Other</td>
                  <td><span class="inlineHeader">acetaminophen</span> 650-975 mg (but avoid if patient has liver disease or injury)</td>
                </tr>
                <tr>
                  <td>Ca<sup>2+</sup> blocker</td>
                  <td><span class="inlineHeader">dantrolene**</span> (for malignant hyperthermia, posturing, rigidity. 0.25-2mg/kg q6-12h)</td>
                </tr>
                <tr>
                  <td>Non-pharma</td>
                  <td>Cooling blankets, nasogastric tube lavage</td>
                </tr>
              </tbody>
            </table>
          </div>

          <p>*Anterior hypothalamus is temperature sensitive, and the posterior hypothalamus is the heat dissipation center</p>
          <p>**dantrolene is not on the formulary at Mount Sinai.</p>

       </div>
      </div>


      <div class="list-block accordion-list">       
        <ul>
          <li class="accordion-item">
            <a href="#" class="item-content item-link">
              <div class="item-inner">
                <div class="item-title">References</div>
              </div>
            </a>
        
            <div class="accordion-item-content">
              <div class="content-block">

                <p>Elovic E, Baerga E, Galang GF, Cuccurullo SJ, Reyna M, Malone RJ. Physical Medicine and Rehabilitation Board Review. 3rd ed. New York, NY: Demos Medical; 2015. Chapter 2, Traumatic Brain Injury. P.96-146.</p>

                <p>Baguley IJ, Perkes IE, Fernandez-Ortega JF, Rabinstein AA, Dolce G, Hendricks HT for the Consensus Working Group. Paroxysmal Sympathetic Hyperactivity after Acquired Brain Injury: Consensus on Conceptual Definition, Nomenclature, and Diagnostic Criteria. Journal of Neurotrauma. August 2014, 31(17): P.1515-1520.</p>

                <p>Feng Y, Zheng X, Fang Z. Treatment Progress of Paroxysmal Sympathetic Hyperactivity after Acquired Brain Injury. Pediatr Neurosurg. 2015;50(6):301-9.</p>

              </div>
            </div>
          </li>
        </ul>
      </div>

    </div>
  </div>
</div>
